



DISPATCH OF SCHEME BOOKLET

19 May 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (**Mayne Pharma**) refers to its announcement on 15 May 2025 (**Scheme Booklet Announcement**) in relation to the registration of an explanatory statement with the Australian Securities & Investments Commission which includes information about the Scheme, the Independent Expert's report and the notice convening the Scheme Meeting (**Scheme Booklet**) in relation to the proposed acquisition by Cosette by way of a scheme of arrangement (**Scheme**).

Mayne Pharma advises that the Scheme Booklet has been dispatched to Mayne Pharma Shareholders in the manner set out in the Scheme Booklet Announcement.

If shareholders have any questions in relation to the Scheme Booklet or the Scheme, they should contact the Mayne Pharma Shareholder Information Line on 1300 158 729 (within Australia) and +61 2 9066 4058 (outside Australia), Monday to Friday between 9.00am and 5.00pm (AEST) (excluding public holidays).

- ENDS -

Authorised for release to the ASX by the Board Chair

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.